Tag: Tuberculosis
Dexamethasone No Benefit in HIV-Positive With Tuberculous Meningitis
No survival benefit or benefit in any secondary end point seen for adjunctive dexamethasone versus placebo
USPSTF Recommends Screening At-Risk Persons for Latent TB Infection
Moderate net benefit found for preventing active tuberculosis disease by screening persons at increased risk for infection
USPSTF Recommends Screening At-Risk Persons for Latent TB Infection
Moderate net benefit found for preventing active tuberculosis disease by screening persons at increased risk for infection
Mortality High for Patients With Concurrent TB, COVID-19
In adjusted analysis, 31 percent of people with concurrent diseases died
Incidence of Tuberculosis Up to 2.5 Cases Per 100,000 in U.S. in 2022
Compared with 2021, in 2022, TB incidence was higher among persons aged 4 years and younger and 15 to 24 years and lower in those aged 65 years and older
Eight-Week Bedaquiline-Linezolid Noninferior for TB
Eight-week treatment noninferior to standard regimen for composite of death, ongoing treatment, active disease at week 96
USPSTF Recommends Screening for Latent TB Infection
Task force recommends screening asymptomatic adults at increased risk for latent TB infection
Bedaquiline-Pretomanid-Linezolid Regimens Compared for XDR TB
Overall risk-benefit ratio seems to favor patients receiving linezolid at dose of 600 mg for 26 weeks
Multidose BCG Protects Against COVID-19 in At-Risk Individuals
Efficacy of 92 percent found among at-risk COVID-19-unvaccinated individuals with type 1 diabetes
Among Persons With HIV, More Finish Short-Course TB Prophylaxis
Treatment completion 90.4 percent for three months of rifapentine-isoniazid versus 50.5 percent for six months of isoniazid